These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18799883)

  • 1. Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography.
    Oberholzer PA; Urosevic M; Steinert HC; Dummer R
    Dermatology; 2008; 217(4):351-5. PubMed ID: 18799883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
    Mruck S; Baum RP; Rinne D; Hör G
    Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
    Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
    Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
    Ortiz B; Vázquez C; Martínez C; Giménez J; Sanmartín O; de los Dolores V; Ortega F; Maíquez J; Fliquete MV
    Rev Esp Med Nucl; 2003; 22(2):87-96. PubMed ID: 12646097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
    Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
    Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
    Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
    Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum S100--a marker for disease monitoring in metastatic melanoma.
    Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
    Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
    Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
    BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
    Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
    Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100 protein serum levels in cutaneous malignant melanoma.
    Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
    Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
    Jury CS; McAllister EJ; MacKie RM
    Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100 serum level: a tumour marker for metastatic melanoma.
    Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
    Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
    Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
    Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
    Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
    Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
    Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.